#USA #Boston #gene therapy #Solvias #QC Strategies

Solvias Showcases Advanced Quality Control Strategies at Cell & Gene Therapy International 2025

In an era where the demand for next-generation therapies is escalating, maintaining high-quality standards in cell and gene therapy (CGT) manufacturing is more crucial than ever. Solvias, a key player in the chemistry and manufacturing controls sector, is set to present its latest advancements at the upcoming Cell & Gene Therapy International (CGTI) 2025. This notable event will take place from September 16 to 18, 2025, in Boston, Massachusetts, parallel to the BioProcess International conference.

William Mauck, the Team Lead Manager at Solvias' Molecular Biology Lab, will take the stage to unveil innovative multilayered quality control (QC) strategies that can elevate the quality of CGT processes and solutions. He will shed light on the session titled, "Multilayered QC in CGT From Vector Fidelity to Epigenetic Regulation," where he will address industry challenges such as ensuring vector fidelity and implementing rigorous analytics.

The Future of CGT Manufacturing

Mauck’s presentation will specifically delve into advanced large molecule characterization, vector insertion mapping, and the detection of adventitious viruses through next-generation sequencing (NGS). These methodologies can significantly enhance the QC processes vital for ensuring patient safety and product reliability.

"Multilayered quality control enables us to bring together powerful tools such as real-time genomic monitoring, precise vector validation, and early contaminant detection," said Mauck. These capabilities, he emphasized, are critical for maintaining the consistency and effectiveness of therapies throughout their development phases. By harnessing these advanced strategies, Solvias is poised to support CGT developers in navigating the complex landscape of regulatory expectations while ensuring responsible and reliable therapeutic advancements.

Insights from the Conference

The CGT conference annually gathers the brightest minds in the industry, focusing on innovative manufacturing techniques and analytics strategies designed to scale autologous, allogeneic, and gene-edited therapies. Mauck's session will run on September 17, 2025, from 3:15 PM to 3:45 PM ET, showcasing the company’s commitment to enhancing the manufacturing quality and investment returns in this burgeoning field.

Solvias, with 25 years of experience and a strong presence in the global life sciences market, is recognized for its unrivaled proficiency in chemistry, manufacturing, and control analytics. This been reflected in their efforts to provide end-to-end solutions ranging from raw material testing to drug product release.

Based in Switzerland and adhering to the highest standards set by global agencies, Solvias operates six Centers of Excellence worldwide. They continue to be at the forefront of CMC services for small molecules, biologics, and gene therapies, efficiently addressing the needs of clients in the life sciences sector.

With increased interest from investors and stakeholders eyeing the therapeutic potential of CGT, the insights shared during the conference will likely impact the future direction of CGT quality control methodologies.

Conclusion

Solvias' approach emphasizes the integration of advanced methodologies, vital for fortifying the credibility and safety of CGT products. As the CGT landscape continues to evolve, conferences like CGTI 2025 provide an essential platform for experts to collaborate and innovate towards a future where safe and effective therapies are accessible to all.

For more information about Solvias and its commitment to quality and innovation in CGT manufacturing, visit solvias.com.